SCHEMBL14327129

SCHEMBL14327129

CCC(CCN(C)CCO)c1cc(-c2ccc3c(N)n(Cc4ccccc4)nc3c2)c2c(NC)ncnn12

nearest known ligand 0.32

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
▸ EGFR P00533 1/20 0.32
▸ ERBB2 P04626 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14327089 0.71 CFTR (0.38) —
SCHEMBL14313199 0.65 TYRO3 (0.53) —
SCHEMBL14313868 0.64 TYRO3 (0.53) —
SCHEMBL14312849 0.64 TYRO3 (0.52) —
SCHEMBL14312685 0.64 MERTK (0.44) —
SCHEMBL14327110 0.64 ACVRL1 (0.42) —
SCHEMBL14313867 0.63 TYRO3 (0.45) —
SCHEMBL14313069 0.63 TYRO3 (0.46) —
SCHEMBL5074847 0.62 ACVRL1 (0.61) —
SCHEMBL14327120 0.62 TYRO3 (0.53) —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1945222-B1 PYRROLO[2,1-F] [1,2,4]-TRIAZIN-4-YLAMINES AS IGF-1R KINASE INHIBITORS FOR THE TREATMENT OF CANCER AND OTHER HYPERPROLIFERATIVE DISEASES Bayer Pharma AG (DE) 2012-12-26 — — EP disclosed
Send feedback